High dose chemotherapy and autologous stem cell transplantation with melphalan in patients with monoclonal immunoglobulin deposition disease associated with multiple myeloma

被引：0

作者：

Hassoun, Hani ^{[1
]}

Rafferty, Brian T. ^{[1
]}

Flombaum, Carlos ^{[1
]}

D'Agati, Vivette D. ^{[2
]}

Klimek, Virginia M. ^{[1
]}

Cohen, Adam ^{[1
]}

Boruchov, Adam ^{[1
]}

Kewalramani, Tarun ^{[1
]}

Reich, Lilian ^{[1
]}

Landau, Heather ^{[1
]}

Nimer, Stephen D. ^{[1
]}

Comenzo, Raymond ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[2] Columbia Univ, Med Ctr, New York, NY 10027 USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：360B / 360B

页数：1

共 50 条

[31] Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma
Wichert, Stina
Pettersson, Asa
Hellmark, Thomas
Johansson, Asa
Hansson, Markus
EXPERIMENTAL HEMATOLOGY, 2016, 44 (05) : 342 - 351
[32] High dose melphalan conditioning in autologous stem cell transplantation for multiple myeloma-a UK survey of practice
Smith, S.
Duncan, N.
Scarfe, H.
Davies, E.
Shah, R.
Maouche, N.
Connolly, S.
Gabriel, S.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 454 - 455
[33] Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma
Buadi, Francis K.
Gertz, Morie A.
Laplant, Betsy R.
Halvorson, Alese
Lacy, Martha Q.
Hayman, Suzanne R.
Dingli, David
Kapoor, Prashant
Gonsalves, Wilson I.
Miceli, Teresa
Brandes, Eva
Stafford, Scott L.
Martenson, James A.
Hogan, William J.
Kumar, Shaji K.
BLOOD, 2016, 128 (22)
[34] HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: ACHIEVEMENT OF COMPLETE REMISSION IS ASSOCIATED WITH IMPROVED SURVIVAL
Kumar, L.
Ghosh, J.
Ganessan, P.
Gupta, A.
Hariprasad, R.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 69 - 69
[35] Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation
Sharma, Atul
Lokeshwar, Nilesh
Raina, Vinod
Mohanti, Bidhu K.
Kumar, Rajive
NATIONAL MEDICAL JOURNAL OF INDIA, 2007, 20 (03): : 121 - 124
[36] Intensive therapy with bortezomib and melphalan and autologous stem cell transplantation for patients with multiple myeloma
Luo, Y.
Tan, Y.
He, J.
Shi, J.
Wu, W.
Han, X.
Zheng, G.
Wei, G.
Zheng, W.
Ye, X.
Cai, Z.
Huang, H.
BONE MARROW TRANSPLANTATION, 2011, 46 : S264 - S264
[37] High-dose-Melphalan vs. Busulfan-Melphalan in patients with recurrent multiple myeloma after previous autologous stem cell transplantation
Karp, S.
Haenel, A.
Herbst, R.
Morgner, A.
Thiel, A.
Haenel, M.
ONKOLOGIE, 2012, 35 : 146 - 146
[38] High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: Comparison with a historical control
Capria, S
Petrucci, MT
Pulsoni, A
Ribersani, M
Baldacci, E
de Propris, MS
Meloni, G
ACTA HAEMATOLOGICA, 2006, 115 (1-2) : 9 - 14
[39] Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Rodriguez, Tulio E.
Hari, Parameswaran
Stiff, Patrick J.
Smith, Scott E.
Sterrenberg, Danielle
Vesole, David H.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1391 - 1396
[40] Nonmyeloablative conditioning and allogeneic stem cell transplantation as consolidation therapy after high-dose melphalan and autologous stem cell transplantation for multiple myeloma
Schneider, P
Fenk, R
Bernhard, A
Huenerlituerkoglu, AN
Aivado, M
Wehmeier, A
Pape, H
Haas, R
Kobbe, G
BONE MARROW TRANSPLANTATION, 2002, 29 : S101 - S101

← 1 2 3 4 5 →